Effects of Vitamin D and Calcium Supplementation on Bone of Young Adults After Thyroidectomy of Differentiated Thyroid Carcinoma

Overview

Journal Endocrine

Specialty Endocrinology

Date 2025 Mar 6

PMID 40048011

Authors

Lei Sun

Xiaoyun Lin

Naishi Li

Qian Zhang

Yan Jiang

Ou Wang

Weibo Xia

Xiaoping Xing

Xiaoyi Li

Mei Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Differentiated thyroid carcinoma (DTC) is the most frequent endocrine cancer, with a high incidence in young population. Patients with postoperative DTC are usually considered with increased risk of bone loss, possibly due to the thyroid stimulating hormone (TSH) suppression therapy. However, it remains unclear whether vitamin D and calcium supplementation is beneficial on bone metabolism of young patients with vitamin D malnutrition after thyroidectomy of DTC.

Methods: In this one-year prospective study, adult men younger than 50 years or premenopausal women with DTC and vitamin D insufficiency or deficiency were enrolled after thyroidectomy, who were administered with daily supplements of 1000-2000 IU vitamin D and 600 mg of elemental calcium (calcium-D) or not. Propensity score matching (PSM) was applied to identify baseline-matched cohorts.

Results: A total of 458 patients with a median age of 37 (range 21-50) years were enrolled, with 94 (20.5%) patients supplemented with calcium-D. After PSM, we identified baseline-matched cohorts of 246 DTC patients, of which 82 patients were supplemented with calcium-D and 164 were not. After 12 months' supplementation, lower serum levels of β-CTX (0.27 ± 0.15 vs. 0.35 ± 0.18 ng/ml, P = 0.004), PTH (36.2 ± 12.7 vs. 45.2 ± 14.6 pg/ml, P < 0.001) and higher BMD at lumbar spine (1.8% vs. 0.7%, P = 0.050) and total hip (1.1% vs. -0.4%, P < 0.001) were observed compared to the control group. Among all the 458 patients, increase of 25OHD levels was closely associated with decrease of PTH, ALP and β-CTX levels and improvement in total hip BMD throughout the one-year study period.

Conclusion: Vitamin D and calcium supplements can reduce PTH levels and bone loss, possibly contributing to protecting bone of young DTC patients with vitamin D malnutrition after thyroidectomy.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Lee Y, Yoon B, Lee S, Chung Y, Lee Y . Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer. J Bone Metab. 2019; 26(1):45-50. PMC: 6416149. DOI: 10.11005/jbm.2019.26.1.45. View

Blum M, Bauer D, Collet T, Fink H, Cappola A, da Costa B . Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015; 313(20):2055-65. PMC: 4729304. DOI: 10.1001/jama.2015.5161. View

Wang L, Smith A, Palmer F, Tuttle R, Mahrous A, Nixon I . Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid. 2014; 25(3):300-7. PMC: 6916125. DOI: 10.1089/thy.2014.0287. View

Kim M, Yun K, Kim M, Lim D, Kwon H, Song K . The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone. 2014; 71:101-5. DOI: 10.1016/j.bone.2014.10.009. View

Yoon B, Lee Y, Oh H, Kim S, Lee Y . Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis. J Bone Metab. 2019; 26(1):51-60. PMC: 6416150. DOI: 10.11005/jbm.2019.26.1.51. View

Ku E, Yoo W, Lee E, Ahn H, Woo S, Hong J . Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021; 106(12):3655-3667. DOI: 10.1210/clinem/dgab539. View

Yan X, Thomson J, Zhao R, Zhu R, Wang Z, Zhang N . Vitamin D Status of Residents in Taiyuan, China and Influencing Factors. Nutrients. 2017; 9(8). PMC: 5579691. DOI: 10.3390/nu9080898. View

Li M, Li Y, Deng W, Zhang Z, Deng Z, Hu Y . Chinese bone turnover marker study: reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender. PLoS One. 2014; 9(8):e103841. PMC: 4130521. DOI: 10.1371/journal.pone.0103841. View

10.

Lips P, van Schoor N . The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):585-91. DOI: 10.1016/j.beem.2011.05.002. View

11.

Papaleontiou M, Chen D, Banerjee M, Reyes-Gastelum D, Hamilton A, Ward K . Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study. Thyroid. 2021; 31(9):1383-1390. PMC: 8558057. DOI: 10.1089/thy.2021.0033. View

12.

Holick M . The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017; 18(2):153-165. DOI: 10.1007/s11154-017-9424-1. View

13.

Massimino M, Evans D, Podda M, Spinelli C, Collini P, Pizzi N . Thyroid cancer in adolescents and young adults. Pediatr Blood Cancer. 2018; 65(8):e27025. DOI: 10.1002/pbc.27025. View

14.

Xu N, Wang Y, Xu Y, Li L, Chen J, Mai X . Effect of subclinical hyperthyroidism on osteoporosis: A meta-analysis of cohort studies. Endocrine. 2020; 69(1):39-48. DOI: 10.1007/s12020-020-02259-8. View

15.

Segna D, Bauer D, Feller M, Schneider C, Fink H, Aubert C . Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. J Intern Med. 2017; 283(1):56-72. PMC: 5739958. DOI: 10.1111/joim.12688. View

16.

Svensson J, Ohlsson C, Karlsson M, Lorentzon M, Lewerin C, Mellstrom D . Subclinical hyperthyroidism is associated with increased risk of vertebral fractures in older men. Osteoporos Int. 2021; 32(11):2257-2265. PMC: 8563553. DOI: 10.1007/s00198-021-05964-w. View

17.

De Mingo Dominguez M, Guadalix Iglesias S, Arroba C, Lopez Alvarez B, Diaz-Guerra G, Martinez-Pueyo J . Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy. Endocrine. 2018; 62(1):166-173. DOI: 10.1007/s12020-018-1671-8. View

18.

Moon J, Kim K, Oh T, Choi S, Lim S, Park Y . The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma. J Clin Endocrinol Metab. 2016; 102(1):78-85. DOI: 10.1210/jc.2016-2740. View

19.

Hawkins Carranza F, Guadalix Iglesias S, De Mingo Dominguez M, Arroba C, Lopez Alvarez B, Allo Miguel G . Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy. Cancer Med. 2020; 9(16):5746-5755. PMC: 7433843. DOI: 10.1002/cam4.3200. View

20.

Delitala A, Scuteri A, Doria C . Thyroid Hormone Diseases and Osteoporosis. J Clin Med. 2020; 9(4). PMC: 7230461. DOI: 10.3390/jcm9041034. View